Arcutis (ARQT) Reiterated at Overweight by Cantor Fitzgerald, Company's Opportunity to Become Medical Dermatology Leader Remains Underappreciated
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $50.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
